BMJ Evidence-Based Medicine: 27 (4)

EBM analysis

Mental health: The ‘double whammy’ of low prevalence in clinical risk prediction (13 August, 2021)
Thomas R Fanshawe, Seena Fazel
General medicine: Early experience with the FDA’s regulatory review of novel gene therapies (11 October, 2021)
Jeremy Puthumana, Alexander C Egilman, Reshma Ramachandran, Nida Naushad, Nilay Shah, Joseph Ross
General medicine: Transparency of COVID-19 vaccine trials: decisions without data (9 August, 2021)
Sarah Tanveer, Anisa Rowhani-Farid, Kyungwan Hong, Tom Jefferson, Peter Doshi

Data-dredging bias (20 December, 2021)
Adrian Erasmus, Bennett Holman, John P A Ioannidis
Appraising qualitative health research—towards a differentiated approach (23 September, 2021)
Veronika Williams, Anne-Marie Boylan, Nicola Newhouse, David Nunan

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis (11 October, 2021)
Rini Noviyani, Sitaporn Youngkong, Surakit Nathisuwan, Bhavani Shankara Bagepally, Usa Chaikledkaew, Nathorn Chaiyakunapruk, Gareth McKay, Piyamitr Sritara, John Attia, Ammarin Thakkinstian
Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis (17 November, 2021)
Mathias Maagaard, Emil Eik Nielsen, Naqash Javaid Sethi, Ning Liang, Si-Hong Yang, Christian Gluud, Janus Christian Jakobsen
Interventions for Menière’s disease: an umbrella systematic review (8 November, 2021)
Babette Fiebke van Esch, Hester van der Zaag-Loonen, Tjasse Bruintjes, Ton Kuijpers, Peter Paul G van Benthem